Benralizumab vs Placebo for Hypereosinophilic Syndrome: Phase 3 Trial Correction
Benralizumab, a targeted monoclonal antibody, has demonstrated significant efficacy in reducing eosinophil counts and corticosteroid dependence in patients with Hypereosinophilic Syndrome (HES). A correction published this week in Nature Medicine ... Read More